Xencor, Inc. (XNCR)
XNCR moved a median of +0.09% 30 minutes after news, and -0.24% by the close. How XNCR actually reacts to news — the realized, point-in-time move the market made, measured across 285 labeled events over the last three years with zero look-ahead.
XNCR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 283 |
| 30-min | +0.09% | 52% | 285 |
| 60-min | +0.24% | 54% | 285 |
| to close | -0.24% | 47% | 284 |
| Middle 50% of XNCR reactions | -0.65% to +1.18% |
|---|---|
| Median reaction (30-min) | +0.09% |
| Measured reactions | 285 |
Half of all Xencor, Inc. news events land between -0.65% and +1.18% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How XNCR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -0.08% | 40% | +0.33% |
| Analyst downgrades | 16 | +0.42% | 69% | +1.88% |
| Coverage initiations | 12 | +1.76% | 83% | +1.85% |
| Rating reiterations | 69 | -0.17% | 44% | -0.12% |
| Price-target raises | 10 | +0.18% | 60% | +0.33% |
| Price-target cuts | 18 | -0.50% | 33% | -0.59% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how XNCR ranks against every other measured name →
That’s how XNCR usually reacts — get an email when it moves on news →Email me when XNCR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to XNCR's baseline. Nothing else.
Recent XNCR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Xencor to Present at the 2026 Cantor Global Healthcare Conference | Press release | Business Wire | -2.32% | -2.06% | |
| Form 10-Q Xencor Inc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.50% | -8.93% | |
| Form 8-K Xencor Inc For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -2.50% | -8.93% | |
| Xencor Reports Second Quarter 2026 Financial Results | Press release | Business Wire | -2.50% | -8.93% | |
| Form 8-K Xencor Inc For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | +8.54% | |
| Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter | Press release | Business Wire | +0.56% | +8.54% | |
| Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma | Press release | Business Wire | +0.10% | +19.00% | |
| Form 8-K Xencor Inc For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +2.95% | +8.69% | |
| Form 10-Q Xencor Inc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.34% | -2.61% | |
| Form 8-K Xencor Inc For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -1.34% | -2.61% | |
| Xencor Reports First Quarter 2026 Financial Results | Press release | Business Wire | -1.34% | -2.61% | |
| Form 8-K Xencor Inc For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +1.22% | -4.74% | |
| Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW | Press release | Business Wire | +1.79% | +3.81% | |
| Form 8-K Xencor Inc For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | +1.61% | -6.90% | |
| Form ARS Xencor Inc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.61% | -6.90% | |
| Form DEF 14A Xencor Inc For: Apr 27 | SEC filing · Form DEF | SEC EDGAR | +1.61% | -6.90% | |
| Form DEFA14A Xencor Inc | SEC filing · Form DEFA14A | SEC EDGAR | +1.61% | -6.90% | |
| Form 8-K Xencor Inc For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +0.75% | +0.25% | |
| Form 8-K Xencor Inc For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | -4.39% | -5.82% | |
| Xencor Announces Change to Ultomiris® Royalty Revenue Forecast | Press release | Business Wire | -4.39% | -5.82% | |
| Form 10-K Xencor Inc For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.23% | +8.14% | |
| Form 8-K Xencor Inc For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -3.23% | +8.14% | |
| Form S-3ASR Xencor Inc | SEC filing · Form S-3ASR | SEC EDGAR | -3.23% | +8.14% | |
| Form S-8 Xencor Inc | SEC filing · Form S-8 | SEC EDGAR | -3.23% | +8.14% | |
| Xencor Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | -3.23% | +8.14% | |
| Xencor to Participate at Upcoming Investor Conferences | Press release | Business Wire | +2.11% | -0.25% | |
| Form 8-K Xencor Inc For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +0.90% | -1.39% | |
| Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones | Press release | Business Wire | +0.90% | -1.39% | |
| Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies | Press release | Business Wire | +0.77% | -4.38% | |
| Xencor to Participate at Upcoming Investor Conferences | Press release | Business Wire | -0.57% | +6.06% | |
| Form 10-Q Xencor Inc For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.96% | -2.78% | |
| Form 8-K Xencor Inc For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +3.96% | -2.78% | |
| Xencor Reports Third Quarter 2025 Financial Results | Press release | Business Wire | +3.96% | -2.78% | |
| Form 8-K Xencor Inc For: Oct 24 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | +1.07% | |
| Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma | Press release | Business Wire | -1.12% | +1.73% | |
| Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma | Press release | Business Wire | +0.33% | -3.72% | |
| Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Press release | Business Wire | -0.04% | +6.92% | |
| Xencor to Participate at Upcoming Investor Conferences | Press release | Business Wire | +1.23% | -0.74% | |
| Form 10-Q Xencor Inc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.65% | -4.31% | |
| Form 8-K Xencor Inc For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | -4.31% | |
| Xencor Reports Second Quarter 2025 Financial Results | Press release | Business Wire | +0.65% | -4.31% | |
| Form 8-K Xencor Inc For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | -2.68% | |
| Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors | Press release | Business Wire | +0.06% | -2.68% | |
| Form 8-K Xencor Inc For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -2.39% | -1.84% | |
| Form 10-Q Xencor Inc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.91% | +11.97% | |
| Form 8-K Xencor Inc For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +1.91% | +11.97% | |
| Xencor Reports First Quarter 2025 Financial Results | Press release | Business Wire | +1.91% | +11.97% | |
| Form 8-K Xencor Inc For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -0.67% | +5.66% | |
| Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease | Press release | Business Wire | -0.67% | +5.66% | |
| Form ARS Xencor Inc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -2.59% | +0.18% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the XNCR section they belong to.
Where else XNCR is measured.
XNCR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cellectis S.A. - American Depositary Shares (CLLS) | 285 | -0.01% | 37% |
| Prestige Consumer Healthcare Inc. (PBH) | 285 | -0.11% | 45% |
| NOVELION THERAPEUTICS INC COMMON SHARES (NVLN) | 283 | 0.00% | 42% |
| Tenax Therapeutics, Inc. (TENX) | 283 | -0.29% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Xencor, Inc.'s median reaction calculated?
Every labeled XNCR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 285 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of XNCR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does XNCR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.